Convergence and coevolution of Hepatitis B virus drug resistance

Nature Communications

Volumn 3, Issue , 2012, Pages

  Thai, Hong ^a   Campo, David S ^a   Lara, James ^a   Dimitrova, Zoya ^a   Ramachandran, Sumathi ^a   Xia, Guoliang ^a   Ganova Raeva, Lilia ^a   Teo, Chong Gee ^a   Lok, Anna ^b   Khudyakov, Yury ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; VIRUS PROTEIN; ANTIVIRUS AGENT; RNA DIRECTED DNA POLYMERASE;

ADULT; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COEVOLUTION; CONTROLLED STUDY; CONVERGENT EVOLUTION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; UNINDEXED SEQUENCE; VIRUS GENOME; ANTIVIRAL RESISTANCE; CHILD; CLASSIFICATION; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR EVOLUTION; MOLECULAR GENETICS; PHYLOGENY; VIROLOGY;

HEPATITIS B VIRUS;

ADULT; ANTIVIRAL AGENTS; CHILD; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GENOME, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHYLOGENY; RNA-DIRECTED DNA POLYMERASE; VIRAL PROTEINS;

EID: 84860263316     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1794     Document Type: Article

References (27)

1. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11, 97-107 (2004). (Pubitemid 38365759)
2. Harrison, T. J. Hepatitis B virus: molecular virology and common mutants. Semin. Liver Dis. 26, 87-96 (2006). (Pubitemid 43668251)
3. Zoulim, F. & Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137, 1593-1608 (2009).
4. Hongthanakorn, C. et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 53, 1854-1863 (2011).
5. Soriano, V., Perelson, A. S. & Zoulim, F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J. Antimicrob. Chemother. 62, 1-4 (2008). (Pubitemid 351865869)
6. Khudyakov, Y. Coevolution and HBV drug resistance. Antivir. Ther. 15, 505-515 (2010).
7. Cassino, L., Laufer, N., Salomon, H., Campos, R. & Quarleri, J. Hepatitis B precore/core promoter mutations in isolates from HBV-monoinfected and HBV-HIV coinfected patients: a 3-yr prospective study. J. Clin. Virol. 46, 354-359 (2009).
8. Wang, F. et al. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues. Clin. Ther. 31, 360-366 (2009).
9. Ramachandran, S. et al. Evaluation of intra-host variants of the entire hepatitis B virus genome. PLoS One 6, e25232 (2011).
10. Angus, P. et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125, 292-297 (2003). (Pubitemid 36929407)
11. Forbi, J. C. et al. Epidemic history and evolutionary dynamics of hepatitis B virus infection in two remote communities in rural Nigeria. PLoS One 5, e11615 (2010).
12. Zhou, Y. & Holmes, E. C. Bayesian estimates of the evolutionary rate and age of hepatitis B virus. J. Mol. Evol. 65, 197-205 (2007). (Pubitemid 47383777)
13. Lewin, S. R. et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 34, 1012-1020 (2001). (Pubitemid 33032037)
14. Murray, J. M., Purcell, R. H. & Wieland, S. F. The half-life of hepatitis B virions. Hepatology 44, 1117-1121 (2006). (Pubitemid 44748363)
15. Margeridon-Thermet, S. et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J. Infect. Dis. 199, 1275-1285 (2009).
16. Chotiyaputta, W. & Lok, A. S. Hepatitis B virus variants. Nat. Rev. Gastroenterol. Hepatol. 6, 453-462 (2009).
17. Colonno, R. J. et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44, 1656-1665 (2006). (Pubitemid 44953670)
18. Ramachandran, S., Xia, G. L., Ganova-Raeva, L. M., Nainan, O. V. & Khudyakov, Y. End-point limiting-dilution real-time PCR assay for evaluation of hepatitis C virus quasispecies in serum: performance under optimal and suboptimal conditions. J. Virol. Methods 151, 217-224 (2008).
19. Excoffier, L., Laval, G. & Schneider, S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol. Bioinform. Online 1, 47-50 (2005).
20. Posada, D. & Crandall, K. A. MODELTEST: testing the model of DNA substitution. Bioinformatics 14, 817-818 (1998). (Pubitemid 28552116)
21. Felsenstein, J. Evolutionary trees from DNA sequences: a maximum likelihood approach. J. Mol. Evol. 17, 368-376 (1981). (Pubitemid 11016207)
22. Kosakovsky Pond, S. L., Frost, S. D. & Muse, S. V. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21, 676-679 (2005). (Pubitemid 40424796)
23. Saitou, N. & Nei, M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406-425 (1987).
24. Jensen, F. In Bayesian Networks and Decision Graphs 18-20 (Springer-Verlag, 2001).
25. Dash, D. & Druzdzel, M. J. In Proceedings of the Nineteenth Annual Conference on Uncertainty in Artificial Intelligence (UAI-03) (ed. Morgan Kaufmann, 167-174 2003).
26. Cooper, G. F. & Herskovits, E. A Bayesian method for the induction of probabilistic networks from data. Mach. Learn. 9, 309-347 (1992).
27. Kullback, S. & Leibler, R. A. On Information and Sufficiency. Ann. Math. Stat. 22, 79-86 (1951).